Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provided earnings guidance for the year ended December 31, 2021. For the year ended December 31, 2021, the company expects net profit attributable to shareholders of the listed company of RMB 275.0 million to RMB 412.5 million. Basic earnings per share expected to in the range of RMB 0.1874 per share to RMB 0.2811 per share.